Reports Q1 revenue $26.22M, consensus $26.13M. “In the first quarter, Autolus continued to expand market share for AUCATZYL in the US based on strong physician experience in adult ALL, and supported by reliable, high-quality product delivery. Our UK launch, which began in January, is off to a strong start, and we are expanding our reach in this market as well. We are pleased to report a turn to positive gross margin in the first quarter, and we expect continued improvement as we grow sales and manage costs,” said Christian Itin, CEO of Autolus.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUTL:
- Autolus Therapeutics (AUTL) Q1 Earnings Cheat Sheet
- Analyst Maintains Buy on Autolus, Reiterates $9 Price Target on Restructuring Savings and Clinical Catalysts
- Autolus Therapeutics Announces Workforce Reduction and Cost Restructuring
- Autolus Therapeutics to reduce workforce by approximately 13%
- Autolus Therapeutics: Strategic Positioning and Leadership Drive Confident Buy Rating